Related Experiment Video
Updated: May 3, 2026
09:29
An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice
Published on: July 14, 2023
1.4K
Soluble ST2 and galectin-3 in heart failure.
Ravi V Shah1, James L Januzzi1
1Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.
Clinics in Laboratory Medicine
|February 11, 2014
Summary
New biomarkers beyond natriuretic peptides are crucial for accurately assessing heart failure (HF) progression and patient risk. These novel markers offer deeper insights into HF pathophysiology for improved clinical management.
Area of Science:
- Cardiology
- Biomarker Discovery
- Heart Failure Pathophysiology
Background:
- Accurate risk stratification in heart failure (HF) requires biomarkers reflecting disease progression, hemodynamics, and ventricular remodeling.
- Natriuretic peptides are established HF biomarkers, but residual risk necessitates complementary markers.
- Understanding molecular pathophysiology is key to improving HF patient outcomes.
Purpose of the Study:
- To summarize current literature on novel biomarkers for HF diagnosis and risk stratification.
- To explore biomarkers beyond natriuretic peptides that complement existing diagnostic tools.
- To highlight the role of molecular markers in understanding HF.
Main Methods:
- Literature review of studies on circulating biomarkers in heart failure.
- Analysis of data on biomarker performance in HF diagnosis and prognosis.
- Synthesis of findings on novel biomarkers and their clinical utility.
Main Results:
- Circulating biomarkers offer molecular insights into HF progression, hemodynamics, and remodeling.
- Novel biomarkers show potential to complement natriuretic peptides in risk stratification.
- Current literature supports the investigation of additional biomarkers for HF management.
Conclusions:
- Biomarkers beyond natriuretic peptides are essential for comprehensive HF risk assessment.
- Further research into novel biomarkers can refine HF diagnosis and treatment strategies.
- Molecular-level insights from biomarkers improve understanding and management of heart failure.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
1.9K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K
01:26Heart Failure III: Clinical Manifestations
1.2K
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
1.2K
01:26Heart Failure Drugs: Inotropic Agents
2.0K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
765
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
765
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
01:22Heart Failure Drugs: Diuretics
1.6K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.6K